Shorla Pharma Sees Opportunity In Re-Innovated Oncology Drugs

Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.  

Shorla Pharma
Orlaith Ryan And Sharon Cunningham • Source: Shorla Pharma

Shorla Pharma is hoping its agility and speed to market will help it stand out in the crowded oncology field, with the company seeing potential in “re-innovated” therapies that might relieve the burden on patients, especially in a post-COVID-19 era.

Headquartered in Questum, a Clonmel, Ireland-based acceleration center, Shorla Pharma is led by co-founders Sharon Cunningham and Orlaith Ryan

The series A round, which closed in June 2020, was led by Seroba Life Sciences, a European venture capital firm headquartered in Dublin, Ireland, with additional investment from Irish and

More from Start-Ups & SMEs

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business